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Objective: There are very few population-based studies of long-term outcomes after lower extremity (LE) bypass graft
surgery. This study analyzes perioperative and long-term limb salvage and amputation-free survival outcomes for patients
undergoing initial aortoiliac or femoropopliteal bypass graft surgery in California hospitals from 1996 to 1999.
Methods:Administrative data with encrypted identifiers were used to identify a chronologically first, index admission of all
patients undergoing LE bypass procedures for occlusive disease from 1996 to 1999. A 1993 to 1995 look-back period
was used to exclude patients who had undergone prior bypass surgery or amputation procedures. Patients with incident
procedures were then followed forward to determine subsequent hospitalizations and vital status through 2004. The
study comprised 28,128 patients discharged from 345 California hospitals with a median 61.5-month follow-up. Risk
factors included demographic characteristics, comorbid conditions, admission type, gangrene or ulceration, operation
level, hospital LE bypass surgery volume, and year of discharge. Logistic regression was used to analyze 30-day outcomes,
and Kaplan-Meier analysis and Cox proportional hazard models were used to analyze amputation-free survival.
Results: Overall 30-day mortality was 4.3, and the 30-day major amputation rate was 2.6%. Limb salvage was 81.9% at 5
years and 76.4% at 9 years. Amputation-free survival was 51.5% at 5 years and 34.1% at 9 years. Risk factors were generally
similar for both perioperative and late outcomes. Advanced age, higher comorbidity level, gangrene, and emergency or
nursing home admission conferred significantly greater risk. Hospital volume was associated with both perioperative and
late outcomes. African American and Hispanic patients had much higher amputation rates but did not have higher
mortality risk after controlling for baseline severity of illness.
Conclusions: Long-term outcomes of LE bypass surgery were superior for high-volume hospital patients. Graft surveil-
lance and risk factor follow-up care provide a major opportunity for quality improvement efforts. The contrast between
traditional limb salvage and amputation-free survival outcomes raises questions about the value of surgical treatment,
particularly for patients with limited life expectancy and without coding of tissue loss or critical limb ischemia. (J Vasc
Surg 2009;50:776-83.)By the mid-1990s, meta-reviews of lower extremity
(LE) bypass surgery, based mainly on single-center studies,
provided pooled estimates of 5-year primary patency of 80%
after femoropopliteal vein bypass for disabling claudication
and 66% for critical limb ischemia (CLI), with approxi-
mately 15% to 20% lower rates for prosthetic grafts.1 Com-
pared with primary patency, even better results have been
reported for long-term limb salvage, although often
achieved after frequent repeat revascularizations, rehospi-
talizations, and intensive local wound care.2,3 Rarely, how-
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776ever, have large population-based datasets been used to
document rates of limb salvage over a long follow-up
period, including a full description of the burden of mor-
bidity and mortality after an initial surgery.4,5
From the patient perspective, a key long-term outcome
of LE bypass surgery is amputation-free survival, defined as
the time between a patient’s initial bypass surgery oper-
ation and either subsequent major amputation or death.
This was originally termed “cumulative palliation” and is
a benchmark for clinical decisions about which patients
will benefit most from LE bypass surgery.6 Because
amputation and death are both considered failure end
points, amputation-free survival rates will be significantly
lower than crude limb salvage rates computed when
deaths are right censored.
Recent conservative benchmarks include 3-year
amputation-free survival of 57% among 195 surgically
treated patients with critical limb ischemia in the Bypass
Versus Angioplasty in Severe Ischemia of the Leg (BASIL)
trial, three-quarters of whom received vein grafts.7 The
amputation-free survival rate for the 404 LE vein bypass
patients in the PREVENT III study of edofoligide for the
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patients with very high rates of tissue loss and diabetes, was
74.1% at 1 year.8
This study used State of California hospital discharge
data to investigate amputation-free survival for a cohort of
28,000 unique patients who underwent bypass proce-
dures in nonfederal hospitals in California from 1996 to
1999. Cohort inception was based on a chronologically
first index or incident LE bypass surgery determined with
the aid of a 3-year look-back period (1993-1995) to detect
any evidence of any prior bypass operations or amputations.
Each patient in this cohort was then followed for up to 9
years to document subsequent LE bypass procedures or
amputations, as well as vital status, through 2004.
We present 30-day mortality and major complication
rates, and the frequency of subsequent rehospitalization for
bypass surgery, bypass graft revision, or major amputation
during a median 62-month follow-up period. We explore
the association of perioperative and late survival outcomes,
including limb salvage and amputation-free survival, with
patient demographic, clinical, and hospital-level risk factors
at the time of the initial surgery. Our results present a
unique picture of the epidemiology and outcomes of LE
bypass surgery in the period just before the recent rapid
growth of endovascular treatment and use of LE stents.9
METHODS
Data source and selection of index admission records.
The California Office of Statewide Health Planning and
Development (OSHPD) provided patient discharge data
for the study. As part of an approved research protocol,
OSHPD provided an encrypted patient identifier to link
multiple discharges for the same patient over time. The
sample was created to select all unique patients, aged
35 years, undergoing a first aortoiliac-femoral (AI) or
femoropopliteal-distal (FP) bypass graft surgery based on
International Classification of Disease (ICD-9) procedure
codes 39.25 or 39.29. We selected each patient’s chrono-
logically first bypass surgery admission and retained a sam-
ple of these index bypass surgery discharges of unique
individuals during a 4-year accrual period from1996 to 1999.
We excluded patients with a principal diagnosis of aortic
anuerysm to achieve a sample of patients whose hospital
procedures were primarily related to occlusive disease.
Look-back to exclude patients with prior bypass
surgery or amputation. We then sought to exclude from
our analysis any patients with a documented history of LE
bypass surgery or amputation in California hospitals in the
3 years before cohort inception, 1993 to 1995. We identi-
fied and excluded any cohort patient with any previous
admission for through foot, below knee, or above knee
amputation, prior AI or FP procedures, or any prior bypass
graft revision procedures (ICD-9 code 39.49) in 1993 to
1995.
The look-back exlusion was designed to retain the
largest feasible number of first-time, incident LE bypass
procedures as index admissions in our analysis sample. We
did not exclude patients who only underwent prior LEangioplasty, partly because angioplasty ICD-9 procedure
codes do not distinguish procedures anatomically. Finally,
we also excluded patients aged 35 years.
On the basis of prior literature, we expected that ex-
cluding patients found to have previous bypass surgery or
amputation detected during a 3-year period would yield
very high rates of initial bypass procedures among the
remaining cohort.10 We performed an empirical test of the
sensitivity of this 3-year look-back period by examining
themuch longer 5- to 9-year study sample follow-up period
through 2004. By looking at readmission rates during
3-year windows during this follow-up period, we calculated
that6% of our patient cohort would have had undetected
lower extremity procedures performed 3 years after their
index operation. Because almost all study patients had an
even longer look-back than 3 years, we were reasonably
certain that our data reflected patients’ first LE bypass graft
surgery.
Risk factors for perioperative and late outcome
measures. The OHSPD patient files provide information
on age and sex and whether the admission was an emer-
gency or from a nursing home. Race and ethnicity were
classified as Hispanic, African American, or white/other,
the latter category including 3.1% of all patients classified as
Asian and 2.6% as other/unknown. Chronic comorbid
conditions were derived from ICD-9 diagnoses classified by
the Elixhauser method,11 with software distributed by the
Agency for Healthcare Research and Quality.12
The Elixhauser comorbidity codes are derived from
conditions present on admission and found related to death
and resource use.13 We used an equally weighted count of
18 of the most relevant codes with1% prevalence, includ-
ing hypertension, pulmonary, liver, renal, vascular, or cere-
brovascular disease, as well as heart failure or cancer (Ap-
pendix I, online only) to empirically derive five comorbidity
severity levels. When stratified by this comorbidity index,
our study cohort had a linearly decreasing study period
survival ranging from 61% for those with only 1 Elix-
hauser comorbidity, 52.1% for those with 2, 42.0% for
those with 3, 27.9% for those with 4, and only 17.8% for the
small group with 5 conditions.
We also tested whether ICD-9 coded diabetes had an
additional incremental effect on patient outcomes. Severity
of vascular disease and extent of tissue loss are poorly
documented by ICD-9 coding. However, we followed the
literature in identifying patients with gangrene or ulcer-
ation as having the most severe presentation.
Perioperative outcomes included 30-day postproce-
dural mortality and incidence of acute myocardial infarc-
tion (MI), iatrogenic stroke, or major amputation. Mortal-
ity follow-up for all study patients throughDecember 2004
was provided by OSHPD from a link to the state’s vital
status records. Readmissions for lower extremity vascular
surgery or amputation procedures at any nonfederal Cali-
fornia hospital were also tracked through 2004. Less than
1% of all records did not have valid patient identifiers for
linkage to vital status and readmission data and were ex-
cluded from the study.
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mined by time from the index procedure to a failure end
point of either death or major amputation (above or below
knee) before the end of follow-up on December 31, 2004.
Limb salvage was conservatively defined as time to a subse-
quent major amputation before the end of follow-up, cen-
soring death. This is a conservative estimate, because hos-
pital administrative data do not distinguish which leg was
amputated. Because it is impossible to classify whether
subsequent amputations were for an ipsilateral or contralat-
eral limb, any major amputation was counted as evidence of
failure for the initial bypass procedure.
Hospital LE bypass surgery volume. We were able
to compute the cumulative volume of initial LE bypass
surgery at each of the 345 California hospitals in the sample
from 1996 to 1999. This volume estimate varied from a
single operation to 600 patients at the highest-volume
institution, including bypass patients with aneurysm diag-
noses. Although these volume data were limited to the
number of unique bypass patients undergoing largely initial
procedures rather than total vascular surgery procedures
performed, our data nevertheless likely provided a good
measure of relative hospital vascular surgery capacity.14
We empirically categorized hospitals into four annual
LE bypass graft surgery volume strata. Low volume in-
cluded patients discharged from 244 hospitals with a 4-year
total of 120 patients (40 annually), medium volume
included 49 hospitals with 120 to 179 patients, high vol-
ume included 43 hospitals with 180 to 320, and very high
volume included nine hospitals with 320 bypass graft
patients.
Statistical analysis. The significance of bivariate as-
sociations between patient demographic, clinical, and
hospital-level characteristics and 30-day outcomes were
analyzed with 2 tests. Random effects multiple logistic
regression with hospital as the class variable was used to
estimate the likelihood of 30-day death or major complica-
tions, with results adjusted simultaneously for year of op-
eration, patient demographics (age, sex, race, and ethnic-
ity), clinical characteristics (emergency admission, nursing
home admission, Elixhauser comorbidity count, diabetes,
ulceration, gangrene, AI vs FP operation), and hospital
volume level. Long-term amputation-free survival and limb
salvage outcomes were estimated with the Kaplan-Meier
procedure for bivariate comparisons and with Cox propor-
tional hazards models for all variables simultaneously. Stan-
dard errors for Cox regression models were adjusted for the
clustering of patients within hospitals using Huber-White
sandwich estimators. All statistical analyses used Stata 10
software (StataCorp, College Station, Tex).
RESULTS
Rates of prior LE procedures from 1993 to 1995
look-back. The 1996 to 1999 discharges with LE bypass
surgery codes initially included 36,972 unique patients.
When checked against 1993 to 1995 look-back data, 3730
(10.1%) had prior LE bypass or bypass graft revision pro-
cedures between January 1993 and the index procedure in1996 to 1999. These patients also had 1215 (3.3%) docu-
mented prior through foot, below knee, or above knee
amputations. These exclusions, removal of patients aged
35 years (0.9%), and 3000 patients (8.3%) who under-
went AI procedures but had a principal diagnosis of aortic
aneurysm, resulted in a final index admission sample of
28,128 patients who underwent initial LE bypass proce-
dures at 345 California hospitals between 1996 and 1999.
Operation level, indications, and overall survival.
There were 23,014 patients (81.8%) with initial FP proce-
dures, including 431 (1.5%) with both FP and AI codes and
5114 (18.2%) with initial AI procedures. The median fol-
low-up was 61.5 months, and 47.0% of study patients had
survived to the end of follow-up in December 2004.
Kaplan-Meier survival probabilities were 80.5% at 1 year,
54.5% at 5 years, and only 38.0% at 9 years (all standard
error 0.004). The number of new patients undergoing
initial LE bypass procedures declined slightly across the
study period, ranging from a high of 7096 in 1996 to 6997
in 1999.
Perioperative outcomes. Table I presents periopera-
tive mortality and major complication rates by key sample
characteristics. The overall 30-day mortality rate was 4.3%
for all patients, 4.2% after FP, and 4.5% after AI procedures.
Rates at 30-days were 2.3% overall for inpatient MI or
iatrogenic stroke, 2.6% overall for below or above knee
amputation (3.0% for FP patients; 1.0% for AI patients),
and 1.4% for FP but only 0.2% for AI patients for through
foot amputation (data not shown).
Mortality rates increased significantly by age. White/
other and Hispanic patients had higher 30-day mortality,
but African-American and Hispanic patients had more than
twice the 30-day major amputation rate. Significantly
higher 30-day mortality differences were evident by admis-
sion status (emergency or nursing home), comorbidity
counts exceeding 2, and for patients with gangrene. Mor-
tality varied inversely by hospital volume level. The nine
highest volume hospitals had a much lower 30-day mortal-
ity (3.0%) compared with the 244 low-volume institutions
(5.1%). The trend towards lower mortality by year was not
significant.
Readmission rates for subsequent bypass surgery or
major amputation. During the follow-up period, 8188
patients (29.1%) were readmitted for at least one (and up to
19) subsequent bypass graft surgery or revision procedures,
including 31.4% of FP and 18.8% of AI patients. Many
more patients were readmitted for an additional FP proce-
dure (21.9%) than for a subsequent AI procedure (2.5%),
which explains the much higher FP/AI ratio derived from
studies based on admissions rather than patients. Alto-
gether, 4796 of study patients (17.1%) underwent major
amputation during the follow-up period, comprising 19.7%
of FP and 5.3% of AI patients (P  .0001). Major ampu-
tation rates were much higher among patients undergoing
subsequent bypass or revision procedures, comprising
29.9% of readmitted FP and 15.6% of readmitted AI pa-
tients (P  .0001).
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Kaplan-Meier amputation-free survival estimates for all pa-
tients were 78.1% at 1 year, 62.9% at 3 years, 51.1% at 5
years, and 34.1% at 9 years. In contrast, limb salvage
calculated with deaths censored was 90.7% at 1 year, 85.5%
at 3 years, 81.9% at 5 years, and 76.4% at 9 years (all
standard error 0.004). Fig 1 displays amputation-free
survival probabilities by operation level for subsequent
major amputations. There was a 20% difference by initial
operation level by the end of the follow-up period. Fig 2
presents survival probabilities for limb salvage, indicating a
widening gap between FP and AI patient amputation rates
over time, with FP patients dipping below a 75% rate at
Table I. Perioperative mortality and complications after lo
index admissionsa to 345 California hospitals
Variables Patients (% of sample)
Demographics
Age, yb
35-54 10.3
55-64 19.9
65-69 16.2
70-74 18.7
75-79 17.5
80 17.4
Gender
Male 56.1
Female 43.9
Race and ethnicityb
African American 9.1
Hispanic 12.9
White/other 78.0
Clinical variables
Operation levelb
Aortoiliac 18.2
Femoropopliteal 81.8
Ulceration 15.6
Gangrene 22.9
Nursing home admit 2.8
Emergency admit 11.8
Diabetes 39.5
Elixhauser comorbidities, No.b
1 23.2
2 33.7
3 26.5
4 11.7
5 4.5
Hospital LE bypass surgery volumeb
Low, 40/y 31.6
Medium, 40-60/y 23.4
High, 61-80/y 32.9
Very high, 80/y 12.1
Year of discharge
1996 25.2
1997 24.8
1998 23.1
1999 24.9
LE, Lower extremity; MI, myocardial infarction.
aThe index admission sample was all unique patients undergoing lower extr
surgery, bypass graft revision, or amputation between 1993 and 1995.
bThe significance of 30-day mortality differences was P  .001.about 8 years. Fig 3 presents limb salvage rates by race andethnicity. Limb salvage probabilities for African American
and Hispanic patients dipped below 75% after about 3
years, whereas white/other patients remained well above
90%.
Multivariate risk factors for 30-day mortality and
amputation-free survival. Table II presents odds ratios
derived from the logistic regression model and hazard
ratios derived from the Cox model for patient risk factors.
Confidence intervals that exclude 1.0 are statistically signif-
icant. The logistic model results for 30-day mortality gen-
erally mirror Table I but provide some additional insights,
especially when compared with Cox model results the next
column. As expected, older patients were at higher risk.
extremity bypass surgery from 1996 to 1999 in 28,128
Inpatient MI or stroke, %
30-day postprocedure, %
Mortality Major amputation
1.0 1.6 2.7
1.9 2.9 2.3
2.1 3.1 2.4
2.5 4.6 2.6
2.4 4.9 2.6
3.0 7.5 3.3
2.3 4.0 2.3
2.4 4.5 3.0
1.9 3.5 4.3
2.3 4.4 4.4
2.3 4.3 2.1
2.7 4.5 1.0
2.1 4.5 3.0
2.4 4.1 2.1
3.1 7.4 8.1
2.5 11.0 5.4
3.1 10.9 7.1
2.7 4.6 3.7
1.5 3.1 1.6
1.5 3.1 2.2
2.3 4.4 2.7
4.2 6.7 4.4
6.0 11.4 6.1
1.9 5.1 3.0
2.3 4.1 3.0
2.5 4.0 2.3
2.4 3.0 1.8
1.9 4.2 2.9
2.2 4.4 2.6
2.6 4.8 2.5
2.4 3.7 2.5
bypass in 1996 to 1999 without having any previous admissions for bypasswer
emityMen did not differ significantly at 30 days but had worse
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ally protective compared with white/other at 30 days, and
race and ethnicity differences were not significant for
amputation-free survival. FP surgery was 47% less risky at
30 days but conferred a 27% greater risk for amputation-
free survival.
Increasing comorbidity levels were associated with in-
ferior perioperative and late outcomes. Diabetes had no
additive risk for 30-daymortality but conferred additive risk
for late survival. Emergency and nursing home admissions
and gangrene were highly significant risk factors, but cod-
ing of LE ulcer was only significant for late outcomes.
Hospital volume was significant for both early and late
Fig 1. Kaplan-Meier amputation-free survival probabilities by by-
pass surgery level in 5114 patients undergoing aortoiliac (dashed
line) and 23,014 undergoing femoropopliteal bypass (solid line) at
345 California hospitals from 1996 to 1999, with follow-up
through 2004 (P  .0001).
Fig 2. Kaplan-Meier limb salvage probabilities by bypass surgery
level in 5114 patients undergoing aortoiliac (dashed line) and
23,014 undergoing femoropopliteal bypass (solid line) at 345
California hospitals from 1996 to 1999, with follow-up through
2004 (P  .0001).outcomes. The 1999 to 1996 comparison was significantfor declining 30-day mortality only. Year of surgery was not
a significant predictor of amputation-free survival.
DISCUSSION
To our knowledge, this study provides the longest
follow-up period of any population-based study of LE
bypass surgery to date. The only other population-based
study to use longitudinal analyses of LE bypass surgery, that
we are aware of, was the report by Al-Omran et al4 on 1991
to 1998 data fromOntario, Canada. This study used some-
what different terminology and reported higher 5-year
overall patient survival (61.5%), but a similar 5-year limb
salvage rate (83.4%). However, the Ontario study was
primarily concerned with comparisons with endovascular
results. The authors did not report perioperative outcomes
or a combined amputation or death end point, did not use
a look-back procedure to identify index initial operations,
and did not examine the same risk factors.
Outcome findings by hospital volume. In particular,
our study also found that the strong association between
hospital volume and perioperative death15 extends to late
amputation-free survival. This implies that hospital quality
differences may extend to follow-up care and graft surveil-
lance. Indeed, the effect of hospital system quality of care
on late survival outcomes may affect many more lives than
early postoperative quality differences. Follow-up care is
thus a potentially more rewarding target for quality im-
provement than operating room care.16
Race and ethnicity findings. Also of interest was that
after controlling for age and baseline health factors, such as
comorbidity and tissue loss coding, and despite signifi-
cantly higher rates of major amputation, minority patients
actually had better perioperative and essentially identical
amputation-free survival outcomes as white/other race pa-
Fig 3. Kaplan-Meier limb salvage probabilities by race and eth-
nicity for 21,934 white/other race patients (solid line) 2569 Afri-
can American patients (large dashes), and 3625 Hispanic patients
(small dashes) undergoing aortoiliac or femoropopliteal bypass
(N 28,128) at 345 California hospitals from 1996 to 1999, with
follow-up through 2004 (P  .0001).tients. This discrepancy between amputation and death has
bypass
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patients had more than twice the prevalence of gangrene
codes at the initial surgery (34.1% and 36.7% to 19.3%
respectively) and were over-represented among those with
the highest Elixhauser comorbidity counts (23.8% of Afri-
can Americans and 22.1% of Hispanics had 4 comorbid
conditions vs 14.8% of whites). Thus, although minority
patients are known to have higher per capita rates of pe-
ripheral vascular disease and amputation,19-21 there was no
disparity in survival outcomes among bypass surgery pa-
tients in California after controlling for baseline risk.
When is LE bypass surgery merited? The California
and Ontario studies raise important questions about the
well-known divergence between more traditional limb sal-
vage and amputation-free survival results. This discrepancy
Table II. Logistic regression results for 30-day postproced
amputation-free survival in 28,128 index admissionsa to 34
Variables
30-day postpro
OR (9
Demographics
Age, y
35-54 Ref
55-64 1.76 (1
65-69 2.00 (1
70-74 2.91 (2
75-79 3.15 (2
80 4.65 (3
Male 1.03 (0
Race and ethnicity
African American 0.66 (0
Hispanic 0.88 (0
White/other Ref
Clinical characteristics
Operation level
Aortoiliac Ref
Femoropopliteal 0.53 (0
Ulceration 1.09 (0
Gangrene 1.88 (1
Nursing home admit 1.86 (1
Emergency admit 3.18 (2
Diabetes 0.72 (0
Elixhauser comorbidities, No.
1 Ref
2 1.01 (0
3 1.47 (1
4 2.25 (1
5 3.72 (2
Hospital LE bypass surgery volume
Low, 40/y 1.77 (1
Medium, 40-60/y 1.40 (1
High, 61-80/y 1.48 (1
Very high, 80/y Ref
Year of discharge
1996 Ref
1997 1.03 (0
1998 1.08 (0
1999 0.81 (0
CI, Confidence interval; HR, hazard ratio; LE, lower extremity; OR, odds
aIndex admission sample was all unique patients undergoing lower extremity
bypass graft revision, or amputation between 1993 and 1995.has led some to question the benefit of aggressive surgicaltreatment of late-stage peripheral vascular occlusive disease
in the context of the limited life expectancy of many pa-
tients. In a critical review, Nehler et al22 describe overly
aggressive limb salvage as “lesion-focused” rather than
“patient-focused” care. They question whether surgical
revascularization procedures are better than primary ampu-
tation for many patients given limited functional benefits
and the potentially iatrogenic effect of interventional man-
agement on the progression of systemic atherosclerosis.
Goshima et al2 also question traditional limb salvage out-
comes for critical limb ischemia because they may conceal
the major burden of subsequent morbidity in even “suc-
cessful” limb salvage.
The data presented here also provide evidence of high
30-day mortality rates that exceed estimates based solely on
mortality and Cox proportional hazards results for
alifornia hospitals
al mortality
Amputation-free survival over median
62-month follow-up
I) HR (95% CI)
e Reference
.45) 1.21 (1.13-1.29)
.81) 1.47 (1.36-1.56)
.01) 1.71 (1.59-1.84)
.36) 1.99 (1.86-2.13)
.40) 2.60 (2.40-2.91)
.16) 1.15 (1.12-1.18)
.84) 0.98 (0.91-1.04)
.06) 1.00 (0.95-1.05)
e Reference
e Reference
.63) 1.27 (1.21-1.35)
.30) 1.44 (1.38-1.51)
.16) 1.98 (1.90-2.06)
.38) 1.35 (1.22-1.49)
.64) 1.46 (1.37-1.54)
.83) 1.06 (1.02-1.10)
e Reference
.22) 1.13 (1.08-1.19)
.79) 1.41 (1.34-1.48)
.82) 1.92 (1.80-2.05)
.78) 2.54 (2.34-2.76)
.28) 1.25 (1.14-1.37)
.83) 1.20 (1.09-1.32)
.92) 1.18 (1.08-1.29)
e Reference
e Reference
.22) 1.00 (0.96-1.05)
.28) 0.99 (0.94-1.04)
.96) 0.98 (0.93-1.03)
in 1996 to 1999without having any previous admissions for bypass surgery,ural
5 C
cedur
5% C
erenc
.26-2
.43-2
.10-4
.28-4
.38-6
.91-1
.52-0
.73-1
erenc
erenc
.43-0
.91-1
.64-2
.45-2
.77-3
.62-0
erenc
.83-1
.21-1
.80-2
.89-4
.37-2
.07-1
.14-1
erenc
erenc
.87-1
.92-1
.68-0
ratio.inpatient deaths.23,24 This raises further concerns when
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absent. Although 22.9% of study patients had gangrene and
15.6% had ulceration codes, only 10.5% had rest pain and
4.8% had claudication codes, including 11.0% of AI pa-
tients. A large proportion of study patients had generic
principal diagnoses of complications of diabetes, other pe-
ripheral vascular disease, LE thrombosis, or arterial stric-
ture. This lack of documentation of tissue loss leaves doubts
about whether high perioperative death and an increased
risk for subsequent limb-threatening graft failure were ap-
propriate risks for many patients in the sample. The recent
shift to endoluminal interventions, which now use im-
proved guidewire and balloon and stent technologies, no
doubt reflects improved risk stratification, especially for
older patients.25
On the other hand, the high initial mortality and rehos-
pitalization rates described here should be placed in the
context of equally high rates of mortality and subsequent
morbidity after above or below knee amputation.26 In this
study, 9974 of all patients (31.4%) were alive 5 years after
their initial operation without major amputation or subse-
quent bypass or revision procedures. Furthermore, limited
data evaluating functional status and quality of life after LE
bypass indicate that many survivors do maintain indepen-
dent living and walking ability and better quality of
life.27-30 Thus medical decision making for many patients,
especially those with extensive gangrene and advanced re-
nal or heart failure, remains daunting.
Increase in endoluminal therapies and decline of
bypass surgery. In this context, recent reports on endolu-
minal interventions have argued that newer LE angioplasty
and stent technologies achieve equivalent or better second-
ary patency and limb salvage results than bypass graft
surgery.31-33 Detailed recommendations for best practices
have recently been published by Beard,34 with the caveat
that “the lack of published or ongoing randomized con-
trolled trials [is] both surprising and somewhat embarrass-
ing.” Surgical LE bypass procedures have substantially de-
clined nationally, and a large corresponding increase has
occurred in endoluminal procedures.24 National estimates
indicate that 75,000 FP and 16,000 AI procedures
were performed in 2006; down 25% and 35%, respectively,
from 2000.35 However, it remains unclear the extent to
which this decline is due to substitution of endoluminal
procedures or to a decline in critical limb ischemia preva-
lence related to improved care for diabetes and more wide-
spread use of statins.19,36 The major amputation rate in the
United States declined an estimated 14% between 2000
and 2006.35
Limitations. This study is limited by use of adminis-
trative data which do not enable us to assess more detailed
clinical characteristics, including specific bypass procedures
grouped by the two generic ICD-9 codes, or the common
subsequent treatment of contralateral limbs.37 We do not
evaluate procedures performed in Veteran’s Administration
hospitals, which may perform 5% to 10% of all LE bypass
operations for men nationally.38 We do not assess the
contribution of endoluminal interventions to limb salvageoutcomes or their concurrent use in our sample. Perhaps
most importantly, we cannot assess the contribution of LE
bypass surgery to reducing the overall amputation rate in
California. Because the rate of primary amputation (with-
out attempted revascularization) is unknown, the effect of
LE bypass surgery or endoluminal therapies on reducing
the amputation rate will remain obscure and controversial.
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Elixhauser chronic disease comorbidities used to create a
counted five-level comorbidity severity index for 31,220
patients discharged from 345 California hospitals after
lower extremity bypass surgery, 1996 to 1999
Prevalence %
Peripheral vascular disease 88.3
Diabetes mellitus
Without chronic complications 17.8
With chronic complications 18.7
Congestive heart failure 9.2
Renal failure 6.7
Hypertension 54.7
Valvular disease 3.7
Chronic pulmonary disease 24.2
Paralysis 1.8
Other neurologic disorders 2.7
Liver disease 1.0
Deficiency anemias 11.9
Obesity 3.5
Solid tumor without metastasis 1.2
Hypothyroidism 4.8
Coagulopathy 3.0
Fluid and electrolyte disorders 14.4
